Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia

Mario Muñoz Builes, María Vela Cuenca, Jose L Fuster Soler, Itziar Astigarraga, Antonia Pascual Martínez, Jose M Vagace Valero, Hoi Y Tong, Jaime Valentín Quiroga, Lucía Fernández Casanova, Adela Escudero López, Luisa Sisinni, Miguel Blanquer, Isabel Mirones Aguilar, Berta González Martínez, Alberto M Borobia, Antonio Pérez-Martínez, Mario Muñoz Builes, María Vela Cuenca, Jose L Fuster Soler, Itziar Astigarraga, Antonia Pascual Martínez, Jose M Vagace Valero, Hoi Y Tong, Jaime Valentín Quiroga, Lucía Fernández Casanova, Adela Escudero López, Luisa Sisinni, Miguel Blanquer, Isabel Mirones Aguilar, Berta González Martínez, Alberto M Borobia, Antonio Pérez-Martínez

Abstract

Introduction: Acute myeloblastic leukaemia (AML) constitutes the second most common haematological malignancy in the paediatric population. Current treatment regimens are based on the administration of polychemotherapy, combining high doses of cytarabine with anthracyclines and topoisomerase inhibitors. Allogeneic haematopoietic stem cell transplantation (HSCT) is an option for high-risk patients with AML (and for intermediate-risk patients if a sibling donor is available). With this strategy, AML survival has increased substantially; however, it has remained stagnant at approximately 60%, with relapse being the principal culprit. The predominant role of the immune system and natural killer (NK) cells in controlling paediatric AML has gained importance within the context of HSCT. In this protocol, we propose incorporating this cell therapy as an adjuvant treatment through the infusion of activated and expanded haploidentical NK (NKAE) cells in paediatric patients with AML who are in cytological remission after completing consolidation therapy, and with no indication for HSCT.

Methods and analysis: Patients up to 30 years of age, diagnosed with AML, in their first cytological remission, who have completed both the induction and the consolidation phases of chemotherapy and do not meet the criteria for allogeneic HSCT are eligible. The patients will receive two doses of NKAE cells once a week, using a GMP K562-mbIL15-41BBL stimulus from a haploidentical donor and interleukin 2 subcutaneously. The patients will then be followed up for 36 months to assess the primary endpoint, which is the probability of relapse after NK cell infusion.

Ethics and dissemination: This clinical trial was approved by the Clinical Research Ethics Committee of La Paz University Hospital and The Spanish Agency of Medicines and Medical Devices. Findings will be disseminated through peer-reviewed publications, conference presentations and community reporting.

Trial registration number: EudraCT code: 2015-001901-15, ClinicalTrials.gov Identifier: NCT02763475.

Keywords: immunology; leukaemia; paediatric oncology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Treatment schedule. NKAE, activated and expanded natural killer cell.

References

    1. Rubnitz JE, Inaba H, Leung WH, et al. . Definition of cure in childhood acute myeloid leukemia. Cancer 2014;120:2490–6. 10.1002/cncr.28742
    1. Goswami M, Hourigan CS. Novel antigen targets for immunotherapy of acute myeloid leukemia. Curr Drug Targets 2017;18:296–303. 10.2174/1389450116666150223120005
    1. Pui C-H, Carroll WL, Meshinchi S, et al. . Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29:551–65. 10.1200/JCO.2010.30.7405
    1. Bolouri H, Farrar JE, Triche T, et al. . The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med 2018;24:103–12. 10.1038/nm.4439
    1. Rubnitz JE, Inaba H, Ribeiro RC, et al. . NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010;28:955–9. 10.1200/JCO.2009.24.4590
    1. Mailloux AW, Epling-Burnette PK. Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes. Oncoimmunology 2013;2:e22654 10.4161/onci.22654
    1. Steger B, Milosevic S, Doessinger G, et al. . CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT. Immunobiology 2014;219:247–60. 10.1016/j.imbio.2013.10.008
    1. Ruggeri L, Capanni M, Urbani E, et al. . Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097–100. 10.1126/science.1068440
    1. Farag SS, Fehniger TA, Ruggeri L, et al. . Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002;100:1935–47. 10.1182/blood-2002-02-0350
    1. Yoon SR, Kim T-D, Choi I. Understanding of molecular mechanisms in natural killer cell therapy. Exp Mol Med 2015;47:e141–11. 10.1038/emm.2014.114
    1. Siegler U, Meyer-Monard S, Jörger S, et al. . Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy 2010;12:750–63. 10.3109/14653241003786155
    1. Koehl U, Brehm C, Huenecke S, et al. . Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol 2013;3:1–12. 10.3389/fonc.2013.00118
    1. Velardi A, Ruggeri L, Mancusi A. Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant. Curr Opin Hematol 2012;19:319–23. 10.1097/MOH.0b013e32835423c3
    1. Stringaris K, Sekine T, Khoder A, et al. . Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica 2014;99:836–47. 10.3324/haematol.2013.087536
    1. Leung W. Infusions of allogeneic natural killer cells as cancer therapy. Clin Cancer Res 2014;20:3390–400. 10.1158/1078-0432.CCR-13-1766
    1. Nguyen R, Wu H, Pounds S, et al. . A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J Immunother Cancer 2019;7:81 10.1186/s40425-019-0564-6
    1. Fernández L, Leivas A, Valentín J, et al. . How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment? Transfusion 2018;58:1340–7. 10.1111/trf.14573
    1. Vela M, Corral D, Carrasco P, et al. . Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett 2018;422:107–17. 10.1016/j.canlet.2018.02.033
    1. Robertson MJ, Cameron C, Lazo S, et al. . Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. Nat Immun 1996-1997;15:213–26.
    1. Lapteva N, Durett AG, Sun J, et al. . Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 2012;14:1131–43. 10.3109/14653249.2012.700767
    1. Voskens CJ, Watanabe R, Rollins S, et al. . Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res 2010;29:134 10.1186/1756-9966-29-134
    1. Fujisaki H, Kakuda H, Shimasaki N, et al. . Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009;69:4010–7. 10.1158/0008-5472.CAN-08-3712
    1. Leivas A, Pérez-Martínez A, Blanchard MJ, et al. . Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma. Oncoimmunology 2016;5:e1250051 10.1080/2162402X.2016.1250051
    1. González B, Bueno D, Rubio PM, et al. . Aspectos inmunológicos de la leucemia mieloblástica aguda. Anales de Pediatría 2016;84:195–202. 10.1016/j.anpedi.2015.07.004
    1. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. . Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051–7. 10.1182/blood-2004-07-2974
    1. Björklund AT, Carlsten M, Sohlberg E, et al. . Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML. Clin Cancer Res 2018;24:1834–44. 10.1158/1078-0432.CCR-17-3196

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe